Panavance Therapeutics Inc. Created to Transform Cancer Treatment
The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action
Excerpt from the Press Release:
Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications.
GP-2250 is a broadly active, tumor cell selective cancer therapeutic with a unique mechanism of action that, as demonstrated in preclinical research, suppresses cancer cells by disrupting their energy metabolism—bringing about cancer cell death. Panavance’s initial clinical focus is on pancreatic cancer, and the company is conducting preclinical studies to develop GP-2250 for the treatment of other cancers and therapeutic indications.
“Panavance was established by Avensis Pharma AG to pursue the development of GP-2250, a novel compound with great potential. This molecule has demonstrated effectiveness and safety in preclinical studies, and its early clinical results in a Phase 1/2 pancreatic cancer trial across 4 US clinical sites have been encouraging,” said Greg Bosch, Chairman & Chief Executive Officer of Panavance.
“We believe in the potential of GP-2250, and the Panavance team is dedicated to realizing its therapeutic possibilities, starting with pancreatic and gynecological cancers, both of which represent areas with unmet clinical need. Ultimately, we hope to improve and extend the lives of cancer patients.”
To accelerate its capitalization, development, and success, Panavance has assembled an impressive leadership team, board of directors, and clinical and scientific advisors, which include seasoned leaders with life science backgrounds in pharmaceutical drug development, clinical and medical sciences, commercialization, and capital markets.
Learn more about Panavance and GP-2250 at www.panavance.com.
References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Panavance is not responsible for the contents of third-party websites.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?